Molecular Pathogenesis of MDS

A Thomas Look1

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115-6084, USA. thomas_look@dfci.harvard.edu

Insights

Myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD) involve clonal chromosomal deletions that inactivate crucial tumor suppressor genes. Identifying these genes is key to understanding myeloid development and advancing MDS treatments.

Area of Science:

  • Hematology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Clonal hematopoietic stem and progenitor cell disorders, including myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD), significantly impact both pediatric and adult patients.
  • These diseases are characterized by clonal, nonrandom chromosomal deletions (e.g., 7q-, 5q-) that inactivate tumor suppressor genes essential for normal myeloid cell development.
  • Identifying these tumor suppressors is challenging due to large deleted regions and the unclear role of haploinsufficiency versus homozygous inactivation.

Purpose of the Study:

  • To investigate the role of inactivated tumor suppressor genes in the pathogenesis of MDS and MPD.
  • To understand the molecular mechanisms underlying dysfunctional myelopoiesis caused by chromosomal deletions.
  • To identify critical genes lost through deletions that contribute to MDS and MPD.

Main Methods:

  • Analysis of chromosomal deletions in MDS and MPD patient samples.
  • Review of existing literature on genetic features and identified mutations in myeloid diseases.
  • Comparative analysis of large deleted regions to pinpoint candidate tumor suppressor genes.

Main Results:

  • Chromosomal deletions, such as 7q- and 5q-, are common in MDS and MPD, suggesting the inactivation of tumor suppressor genes.
  • While some mutations in known hematopoietic genes (e.g., RUNX1, PU.1) have been identified, most deletion-associated tumor suppressors remain elusive.
  • The precise mechanism of myelopoiesis dysfunction (haploinsufficiency vs. homozygous inactivation) requires further clarification.

Conclusions:

  • Understanding the molecular basis of MDS and MPD, particularly the function of lost tumor suppressor genes, is critical for developing targeted therapies.
  • Advances in MDS treatment are contingent upon a comprehensive understanding of the underlying genetic alterations and their impact on myeloid development.
  • Further research is needed to identify the specific tumor suppressor genes affected by chromosomal deletions in these clonal hematopoietic disorders.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair01:36

Mismatch Repair

Overview
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...